88 related articles for article (PubMed ID: 38451783)
21. ABCB1 limits the cytotoxic activity of TAK-243, an inhibitor of the ubiquitin-activating enzyme UBA1.
Wu Z; Yang Y; Lei Z; Narayanan S; Wang J; Teng Q; Murakami M; Ambudkar SV; Ping F; Chen Z
Front Biosci (Landmark Ed); 2022 Jan; 27(1):5. PubMed ID: 35090310
[TBL] [Abstract][Full Text] [Related]
22. INSM1, a Novel Biomarker for Detection of Neuroendocrine Neoplasms: Cytopathologists' View.
Maleki Z; Nadella A; Nadella M; Patel G; Patel S; Kholová I
Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943408
[TBL] [Abstract][Full Text] [Related]
23. Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway.
Murai Y; Jo U; Murai J; Fukuda S; Takebe N; Pommier Y
iScience; 2021 Oct; 24(10):103173. PubMed ID: 34693224
[TBL] [Abstract][Full Text] [Related]
24. Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11.
Jo U; Murai Y; Takebe N; Thomas A; Pommier Y
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572827
[TBL] [Abstract][Full Text] [Related]
25. SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243.
Murai Y; Jo U; Murai J; Jenkins LM; Huang SN; Chakka S; Chen L; Cheng K; Fukuda S; Takebe N; Pommier Y
Cancer Res; 2021 Jun; 81(11):3067-3078. PubMed ID: 33863777
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Thomas A; Takahashi N; Rajapakse VN; Zhang X; Sun Y; Ceribelli M; Wilson KM; Zhang Y; Beck E; Sciuto L; Nichols S; Elenbaas B; Puc J; Dahmen H; Zimmermann A; Varonin J; Schultz CW; Kim S; Shimellis H; Desai P; Klumpp-Thomas C; Chen L; Travers J; McKnight C; Michael S; Itkin Z; Lee S; Yuno A; Lee MJ; Redon CE; Kindrick JD; Peer CJ; Wei JS; Aladjem MI; Figg WD; Steinberg SM; Trepel JB; Zenke FT; Pommier Y; Khan J; Thomas CJ
Cancer Cell; 2021 Apr; 39(4):566-579.e7. PubMed ID: 33848478
[TBL] [Abstract][Full Text] [Related]
27. CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics.
Luna A; Elloumi F; Varma S; Wang Y; Rajapakse VN; Aladjem MI; Robert J; Sander C; Pommier Y; Reinhold WC
Nucleic Acids Res; 2021 Jan; 49(D1):D1083-D1093. PubMed ID: 33196823
[TBL] [Abstract][Full Text] [Related]
28. UAE1 inhibition mediates the unfolded protein response, DNA damage and caspase-dependent cell death in pancreatic cancer.
Liu Y; Awadia S; Delaney A; Sitto M; Engelke CG; Patel H; Calcaterra A; Zelenka-Wang S; Lee H; Contessa J; Neamati N; Ljungman M; Lawrence TS; Morgan MA; Rehemtulla A
Transl Oncol; 2020 Nov; 13(11):100834. PubMed ID: 32688248
[TBL] [Abstract][Full Text] [Related]
29. High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
Kinder TB; Dranchak PK; Inglese J
ACS Chem Biol; 2020 Jul; 15(7):1974-1986. PubMed ID: 32459468
[TBL] [Abstract][Full Text] [Related]
30. Drug Development Targeting the Ubiquitin-Proteasome System (UPS) for the Treatment of Human Cancers.
Zhang X; Linder S; Bazzaro M
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272746
[TBL] [Abstract][Full Text] [Related]
31. Emerging organoid models: leaping forward in cancer research.
Fan H; Demirci U; Chen P
J Hematol Oncol; 2019 Dec; 12(1):142. PubMed ID: 31884964
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.
Lin GL; Wilson KM; Ceribelli M; Stanton BZ; Woo PJ; Kreimer S; Qin EY; Zhang X; Lennon J; Nagaraja S; Morris PJ; Quezada M; Gillespie SM; Duveau DY; Michalowski AM; Shinn P; Guha R; Ferrer M; Klumpp-Thomas C; Michael S; McKnight C; Minhas P; Itkin Z; Raabe EH; Chen L; Ghanem R; Geraghty AC; Ni L; Andreasson KI; Vitanza NA; Warren KE; Thomas CJ; Monje M
Sci Transl Med; 2019 Nov; 11(519):. PubMed ID: 31748226
[TBL] [Abstract][Full Text] [Related]
33. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.
De Martino MC; van Koetsveld PM; Feelders RA; de Herder WW; Dogan F; Janssen JAMJL; Hofste Op Bruinink D; Pivonello C; Waaijers AM; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocrine; 2019 Jun; 64(3):673-684. PubMed ID: 30838516
[TBL] [Abstract][Full Text] [Related]
34. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.
Zhuang J; Shirazi F; Singh RK; Kuiatse I; Wang H; Lee HC; Berkova Z; Berger A; Hyer M; Chattopadhyay N; Syed S; Shi JQ; Yu J; Shinde V; Tirrell S; Jones RJ; Wang Z; Davis RE; Orlowski RZ
Blood; 2019 Apr; 133(14):1572-1584. PubMed ID: 30737236
[TBL] [Abstract][Full Text] [Related]
35. MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer.
Creemers SG; van Koetsveld PM; De Herder WW; Dogan F; Franssen GJH; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2019 Mar; 26(3):367-378. PubMed ID: 30650062
[TBL] [Abstract][Full Text] [Related]
36. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells.
Best S; Hashiguchi T; Kittai A; Bruss N; Paiva C; Okada C; Liu T; Berger A; Danilov AV
Blood Adv; 2019 Jan; 3(1):51-62. PubMed ID: 30617217
[TBL] [Abstract][Full Text] [Related]
37. Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response.
Nilubol N; Boufraqech M; Zhang L; Gaskins K; Shen M; Zhang YQ; Gara SK; Austin CP; Kebebew E
Oncotarget; 2018 Aug; 9(68):33030-33042. PubMed ID: 30250647
[TBL] [Abstract][Full Text] [Related]
38. Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.
Barghout SH; Patel PS; Wang X; Xu GW; Kavanagh S; Halgas O; Zarabi SF; Gronda M; Hurren R; Jeyaraju DV; MacLean N; Brennan S; Hyer ML; Berger A; Traore T; Milhollen M; Smith AC; Minden MD; Pai EF; Hakem R; Schimmer AD
Leukemia; 2019 Jan; 33(1):37-51. PubMed ID: 29884901
[TBL] [Abstract][Full Text] [Related]
39. Development of new preclinical models to advance adrenocortical carcinoma research.
Kiseljak-Vassiliades K; Zhang Y; Bagby SM; Kar A; Pozdeyev N; Xu M; Gowan K; Sharma V; Raeburn CD; Albuja-Cruz M; Jones KL; Fishbein L; Schweppe RE; Somerset H; Pitts TM; Leong S; Wierman ME
Endocr Relat Cancer; 2018 Apr; 25(4):437-451. PubMed ID: 29371329
[TBL] [Abstract][Full Text] [Related]
40. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.
Hyer ML; Milhollen MA; Ciavarri J; Fleming P; Traore T; Sappal D; Huck J; Shi J; Gavin J; Brownell J; Yang Y; Stringer B; Griffin R; Bruzzese F; Soucy T; Duffy J; Rabino C; Riceberg J; Hoar K; Lublinsky A; Menon S; Sintchak M; Bump N; Pulukuri SM; Langston S; Tirrell S; Kuranda M; Veiby P; Newcomb J; Li P; Wu JT; Powe J; Dick LR; Greenspan P; Galvin K; Manfredi M; Claiborne C; Amidon BS; Bence NF
Nat Med; 2018 Feb; 24(2):186-193. PubMed ID: 29334375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
